Unknown

Dataset Information

0

Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.


ABSTRACT: PURPOSE:Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR sensitizing mutation and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system (CNS) metastases. We present results of a subgroup analysis of Korean patients from the pooled data of two global phase II trials: AURA extension (NCT01802632) and AURA2 (NCT02094261). Materials and Methods:Enrolled patients had EGFR T790M-positive NSCLC and disease progression during or after EGFR-TKI therapy. Patients received osimertinib 80 mg orally once daily until disease progression. The primary endpoint was objective response rate (ORR). RESULTS:In total, 66 Korean patients received osimertinib treatment with a median treatment duration of 19 months. In the evaluable-for-response population (n=62), ORR was 74% (95% confidence interval [CI], 61.5 to 84.5) and median duration of response was 9.8 months (95% CI, 7.1 to 16.8). In the full analysis set (n=66), median progression-free survival was 10.9 months (95% CI, 8.3 to 15.0; data cutoff November 1, 2016), and median overall survival was 29.2 months (95% CI, 24.8 to 35.7; data cutoff May 1, 2018). Eight patients with CNS metastases were evaluable for response, none of whom showed CNS progression. The most common adverse events were rash (53%), cough (33%), paronychia, diarrhea, and decreased appetite (each 32%). CONCLUSION:Efficacy and safety profiles of osimertinib in this subgroup are consistent with the global phase II pooled population, which supports osimertinib as a recommended treatment for Korean patients with T790M positive NSCLC.

SUBMITTER: Ahn MJ 

PROVIDER: S-EPMC6962491 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.

Ahn Myung-Ju MJ   Han Ji-Youn JY   Kim Dong-Wan DW   Cho Byoung Chul BC   Kang Jin-Hyoung JH   Kim Sang-We SW   Yang James Chih-Hsin JC   Mitsudomi Tetsuya T   Lee Jong Seok JS  

Cancer research and treatment 20190723 1


<h4>Purpose</h4>Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR sensitizing mutation and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nervous system (CNS) metastases. We present results of a subgroup analysis of Korean patients from the pooled data of two global phase II trials: AURA extension (NCT01802632) and AURA2 (NCT02094261  ...[more]

Similar Datasets

| S-EPMC6726692 | biostudies-literature
| S-EPMC10902357 | biostudies-literature
| S-EPMC5989837 | biostudies-literature
| S-EPMC9873329 | biostudies-literature
| S-EPMC8345213 | biostudies-literature
| S-EPMC10423102 | biostudies-literature
| S-EPMC8793125 | biostudies-literature
| S-EPMC5455880 | biostudies-literature
| S-EPMC6762027 | biostudies-literature
| S-EPMC5370386 | biostudies-literature